Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710605 | 0.86 | CA1 (0.38) | BCHEALDH1A1SMN1; SMN2 | |
| SCHEMBL3386705 | 0.84 | ALDH1A1 (0.34) | POLBRAB9ABCHEALDH1A1SMN1; SMN2 | |
| SCHEMBL13400165 | 0.79 | AGTR2 (0.35) | BCHEALDH1A1SMN1; SMN2AGTR2MEN1 | |
| SCHEMBL16031752 | 0.79 | SMN1; SMN2 (0.39) | POLBRAB9AALDH1A1SMN1; SMN2AGTR2 | |
| SCHEMBL16031070 | 0.79 | CNR2 (0.38) | POLBALDH1A1SMN1; SMN2AGTR2HSD11B1 | |
| SCHEMBL16031069 | 0.78 | AGTR2 (0.36) | SMN1; SMN2AGTR2HSD11B1 | |
| SCHEMBL1710495 | 0.78 | ALDH1A1 (0.38) | POLBRAB9ABCHEALDH1A1SMN1; SMN2 | |
| SCHEMBL16030863 | 0.78 | NR1H2 (0.36) | POLBRAB9ASMN1; SMN2AGTR2HSD11B1 | |
| SCHEMBL13400290 | 0.78 | HDAC6 (0.36) | BCHEALDH1A1SMN1; SMN2AGTR2MEN1 | |
| SCHEMBL1710885 | 0.78 | BCHE (0.37) | BCHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344451-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010028088-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | POLB 3064/4885RAB9A 2273/4885BCHE 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.